Page 331«..1020..330331332333..340350..»

Archive for the ‘Gene Therapy Research’ Category

The Causes of Bunions EXPLAINED – Video


The Causes of Bunions EXPLAINED
As a podiatrist a very commonly asked question is what caused my bunion, in this video, I attempt to explain the causes of Bunions from high heels to genetics.From:1374sethViews:0 0ratingsTime:01:09More inPeople Blogs

See the rest here:
The Causes of Bunions EXPLAINED - Video

The Wonderful World of Planaria – Genetics 3452 – Video


The Wonderful World of Planaria - Genetics 3452
Group 1 #39;s Video Project for Genetics 3452: PlanariaFrom:Richard RiveraViews:0 0ratingsTime:06:36More inScience Technology

Link:
The Wonderful World of Planaria - Genetics 3452 - Video

Steam Power WITHOUT Boiling? (Brainstorm Ep118) – Video


Steam Power WITHOUT Boiling? (Brainstorm Ep118)
Follow us on Twitter twitter.com Like us on Facebook http://www.facebook.com Nanotechnology News tinyurl.com Neuroscience News tinyurl.com Genetics News tinyurl.com Hosted by http://www.youtube.com Contributors http://www.facebook.com - Raychelle and Monica http://www.facebook.comFrom:qdragon1337Views:196 50ratingsTime:05:30More inScience Technology

Read more from the original source:
Steam Power WITHOUT Boiling? (Brainstorm Ep118) - Video

Are We Close to A Skynet Takeover? – Video


Are We Close to A Skynet Takeover?
Experts at the prestigious University of Cambridge will conduct research into the "extinction-level risks" posed to humanity by artificially intelligent robots. The Cambridge Project for Existential Risk is dedicated to "ensuring that our own species has a long-term future" by studying the risks posed by AI, nanotechnology and biotechnology. "The scientists said that to dismiss concerns of a potential robot uprising would be "dangerous," reports the BBC. The project was co-founded by Huw Price, Bertrand Russell Professor of Philosophy at Cambridge, Martin Rees, Emeritus Professor of Cosmology Astrophysics at Cambridge, and Jaan Tallinn, the co-founder of Skype. It also counts amongst its advisers Max Tegmark, Professor of Physics, MIT and George M Church, Professor of Genetics at Harvard Medical School. An article written by Tallinn and Price warns that artificially intelligent computers or robots could take over "the speed and direction of technological progress itself," and shape the environment of planet earth to their own ends while displaying about as much concern for humanity as we do for a bug on the windscreen. Far from being resigned to works as science fiction such as in the Terminator films, the threat posed by a potential future "rise of the robots" has never been closer to reality. The study echoes the predictions of respected author, inventor and futurist Ray Kurzweil, renowned for his deadly accurate technological forecasts. http://www.infowars.com ORDER THIS ...From:InfowarsHeadlineHDViews:0 0ratingsTime:08:55More inNonprofits Activism

View original post here:
Are We Close to A Skynet Takeover? - Video

PGG Wrightson Stud Tour – Ep 23 – Moto-Nui Romneys – Video


PGG Wrightson Stud Tour - Ep 23 - Moto-Nui Romneys
Rural TV NZ in association with New Zealand #39;s leading agriculture company, PGG Wrightson, present the PGG Wrightson Stud Tour 2012. MOTU-NUI ROMNEYS - Masterton - Taihape - Wyndham This week we catch up with the many families that now make up the Motu-Nui brand of sheep genetics spanning from Taihape to Southland with the hub of the operation based at ICA station the home of Jason LeGrove. Tony Glynn, of RuralTV.co.nz, meets with the satelite studs of Bruce and Carolyn Robertson at Motu-Nui South near Wyndham and Donald Sandra Fannin of Motu-Nui Hiwi near Taihape, who were both well established Romney studs in their own right before coming under the Motu-Nui umbrella. We also catch up with Davey Wendy Moore who look after the Terminal rams at Holmwood and Mike Kate Tosswill who look after the composite rams at Pakaraka both near Masterton According to Castlepoint Station manager, Stu Neale, the Motu-Nui rams are no-nonsense sheep bred on steep hill country. Jason LeGrove - Phone : 06 372 3841 MAKE SURE YOU SUBSCRIBE TO OUR YOU-TUBE CHANNEL TO WATCH THE NEXT EPISODE OF THE PGG WRIGHTSON STUD TOUR! JOIN RURAL TV NZ on FACEBOOK : http://www.facebook.com FOLLOW Us on TWITTER : twitter.comFrom:RURALTVNZViews:0 0ratingsTime:26:59More inEntertainment

Read more:
PGG Wrightson Stud Tour - Ep 23 - Moto-Nui Romneys - Video

Sabrina talks genetics – Video


Sabrina talks genetics
Why people should buy a dog from a breeder who does genetic testing. For the record, Sabrina does not belong to me.From:k9s4happinessViews:2 0ratingsTime:00:50More inPets Animals

Go here to see the original:
Sabrina talks genetics - Video

2012 Winner of the Prime Minister’s MacDiarmid Emerging Scientist Prize – Dr James Russell – Video


2012 Winner of the Prime Minister #39;s MacDiarmid Emerging Scientist Prize - Dr James Russell
Dr James Russell, the 2012 Prime Minister #39;s MacDiarmid Emerging Scientist, describes how his innovative combination of ecology, statistics and genetics is keeping rats away from predator-free islands.From:Aliki WViews:3 0ratingsTime:00:46More inScience Technology

Read more from the original source:
2012 Winner of the Prime Minister's MacDiarmid Emerging Scientist Prize - Dr James Russell - Video

SECRET REVEALED: How to master ANY skill – Video


SECRET REVEALED: How to master ANY skill
See more at: http://www.empowernetwork.com Most people don #39;t know about this secret.. By watching this video, you #39;re going to learn a secret, most people don #39;t know. HOW TO MASTER ANY SKILL * Everything #39;s a skill. If someone has done it - you can do it to. Luck and genetics have very little do do with it. The proof is insurmountable. #1- UNCONSCIOUS INCOMPETENCE We are all unconsciously incompetent at something. We don #39;t know what we don #39;t know. We don #39;t know the little intricacies about what make the possible stuff possible. #2- CONSCIOUS INCOMPETENCE * You know what you don #39;t know. It #39;s like when you were learning how to tie your shoe and you were learning the process, but you were incompetent at it. Just like, you were incompetent in the beginning at driving. #3- CONSCIOUS COMPETENCE * You know now how to do it and you have to think about it as you do it. #4- UNCONSCIOUS COMPETENCE * You don #39;t have to think about doing the thing and you just automatically do it. This is the stage you must strive to aim for - by taking massive action and powerful focus at the stage of "conscious competence" - by constantly doing it, by constantly practicing the "practice". ...and then... there will come a time where it just happens... automatically. THE HIERARCHY OF LEARNING *low - receiving by lecture or reading *better - discussing *one of the best - by teaching SECRET WAY OF LEARNING FAST: Modeling * Find a mentor - find someone who #39;s really good at that skill. Modeling their actions, their ...From:RJ BulaongViews:6 0ratingsTime:18:10More inPeople Blogs

Here is the original post:
SECRET REVEALED: How to master ANY skill - Video

Moby Dick – Dry Weight Yield Results – Video


Moby Dick - Dry Weight Yield Results
# of Plants: 1 Genetics: Dinafem Moby Dick Flowering Time: 67 days Light Source: Blackstar Chrome 720w LED Final Yield: 80.75 GramsFrom:GrowBigTVViews:10 0ratingsTime:00:42More inEducation

Read this article:
Moby Dick - Dry Weight Yield Results - Video

Qrazy Train – Dry Weight Yield Results – Video


Qrazy Train - Dry Weight Yield Results
# of Plants: 1 Genetics: TGA Subcool Qrazy Train Flowering Time: 67 days Light Source: Blackstar Chrome 720w LED Final Yield: 74.91 GramsFrom:GrowBigTVViews:15 0ratingsTime:00:31More inEducation

Go here to see the original:
Qrazy Train - Dry Weight Yield Results - Video

Genetics Video – Group Two Fall 2012 BIOL – Video


Genetics Video - Group Two Fall 2012 BIOL
This is the video. It is about Punnett Squares or sometime. Genetics Video - Group Two Fall 2012 BIOLFrom:Jacob LunaViews:3 0ratingsTime:04:19More inComedy

See the original post here:
Genetics Video - Group Two Fall 2012 BIOL - Video

UNL ASCI100 BQ – Video


UNL ASCI100 BQ
Animal Science 100 class on "Befuddling Questions" about agriculture. Covers how good quality steaks are produced from genetics, nutrition, handling, and processing and is made for younger children. Sources include: Dr. Berger, Dr. Nielsen, Dr. Schmitt, and Dr. Calkins from University of Nebraska-Lincoln.From:Ashley McCoyViews:2 0ratingsTime:05:35More inPeople Blogs

See the rest here:
UNL ASCI100 BQ - Video

Genetics Group 4 Video Quiz – Video


Genetics Group 4 Video Quiz
From:christina solvinViews:1 0ratingsTime:02:59More inPeople Blogs

Follow this link:
Genetics Group 4 Video Quiz - Video

Knockout Mouse – Wiki Article – Video


Knockout Mouse - Wiki Article
A knockout mouse is a genetically engineered mouse in which researchers have inactivated, or "knocked out," an existing gene by replacing it or disrupting it with an artificial piece of DNA. The loss... Knockout Mouse - Wiki Article - wikiplays.org Original @ http All Information Derived from Wikipedia using Creative Commons License: en.wikipedia.org Author: Maggie Bartlett, NHGRI. Image URL: en.wikipedia.org ( This work is in the Public Domain. ) Author: Maggie Bartlett, NHGRI. Image URL: en.wikipedia.org ( This work is in the Public Domain. ) Author: Lexicon Genetics Incorporated Image URL: en.wikipedia.org ( This work is in the Public Domain. ) Author: Kjaergaard Image URL: en.wikipedia.org ( Creative Commons ASA 3.0 )From:WikiPlaysViews:0 0ratingsTime:10:45More inEducation

See the rest here:
Knockout Mouse - Wiki Article - Video

Ceremony for the 100000th rice-breeding cross, a major milestone in IRRI’s 52-year history – Video


Ceremony for the 100000th rice-breeding cross, a major milestone in IRRI #39;s 52-year history
Also see: youtu.be On 29 November 2012, the IRRI community celebrated the 100000th rice breeding cross at IRRI, a true milestone in the Institute #39;s 52-year history existence. The parents for the 100000th cross were IR09M105 and NSICRC 214.The objective of this particular cross was to improve eating quality. Making opening comments at the event were Eero Nissila, head of Plant Breeding, Genetics and Biotechnology at IRRI -www.irri.org - and Glenn Gregorio, senior scientist/plant breeder - http://www.irri.org Special guest at the event was Rizal M. Herrera (see 1:38 and 8:13 into video), who was among the first breeders to make crosses at IRRI in the early 1960s - upcagolden2010.wordpress.com - Mr. Herrera arrived at IRRI in 1961 as a research aide and retired 36 years later in 1997 as a senior assistant scientist. Below is his poem-essay about how, in rice breeding, marriage respects no boundaries. Marriage Respects No Boundaries by Rizal M. Herrera IRRI rice breeder, 1961-97 Innocent-looking rice plants also engage in courtship and marriage practices. The rites are simple, devoid of elegant, expensive entourage, and there are no high government officials in flashy cars acting as principal sponsors. The bride, the superstar of the occasion, is not in the usual wedding gown attraction. She is not clad in almost see-through Pitoy #39;s creation from veil to trailings. She is simply a dark green rice plant with flowers stripped off its anthers, the male counterpart of the species. When ...From:irrivideoViews:12 1ratingsTime:10:26More inEducation

Continued here:
Ceremony for the 100000th rice-breeding cross, a major milestone in IRRI's 52-year history - Video

Gene Knockout – Wiki Article – Video


Gene Knockout - Wiki Article
A gene knockout (abbreviation: KO) is a genetic technique in which one of an organism #39;s genes is made inoperative ("knocked out" of the organism). Also known as knockout organisms or simply knockouts... Gene Knockout - Wiki Article - wikiplays.org Original @ http All Information Derived from Wikipedia using Creative Commons License: en.wikipedia.org Author: Maggie Bartlett, NHGRI. Image URL: en.wikipedia.org ( This work is in the Public Domain. ) Author: Maggie Bartlett, NHGRI. Image URL: en.wikipedia.org ( This work is in the Public Domain. ) Author: en.wikipedia.org Image URL: en.wikipedia.org ( Copyright holder allows use with attribution. ) Author: Lexicon Genetics Incorporated Image URL: en.wikipedia.org ( This work is in the Public Domain. )From:WikiPlaysViews:0 0ratingsTime:05:23More inEducation

Go here to read the rest:
Gene Knockout - Wiki Article - Video

Crops and Climate Proofing – Trude Schwarzacher and Pat Heslop Harrison for IAEA – Video


Crops and Climate Proofing - Trude Schwarzacher and Pat Heslop Harrison for IAEA
Superdomestication and feed-forward plant breeding: Genomic and molecular cytogenetic approaches Pat Heslop-Harrison and Trude Schwarzacher, University of Leicester, UK phh4(a)le.ac.uk and ts32(a)le.ac.uk http://www.molcyt.com Today I am presenting some of our work contributing and relating to the IAEA/FAO Coordinated Research Programme on Climate Proofing of Food Crops: Genetic Improvement for Adaptation to High Temperatures in Drought Prone Areas and Beyond (www.webcitation.org ) We all know why we are here and having these important discussions, and climate change and its mitigation are critical: this was the top story on the IAEA homepage last month, reporting on a talk by Modibo Traore: he noted how we have the combination of climate change damaging soil and threatening agriculture as we practice it now, along with unprecedented numbers of people to feed. Some of the challenges are summed up in this photograph from south of Addis Abbaba in the the Rift Valley of Ethiopia. Drought and unpredictable climate prevent crops timely establishment of crops, and the consequences are exacerbated by overgrazing and collection of trees for fuelwood, themselves consequences of population growth, and all leading to loss of soil - seen in the dust storm on the left. In the background though, you can see the product of one of the huge natural resources of Ethiopia: carbon-free electricity from hydroelectric and geothermal sources, rather than nuclear, and certainly part of the solution to ...From:Pat Heslop-HarrisonViews:3 0ratingsTime:18:20More inEducation

Read more here:
Crops and Climate Proofing - Trude Schwarzacher and Pat Heslop Harrison for IAEA - Video

Seattle Genetics Receives FDA Orphan Drug Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL). Seattle Genetics and its ADCETRIS collaborator, Millennium: The Takeda Oncology Company, are conducting the ALCANZA trial, a phase III clinical trial of ADCETRIS for patients with CD30-positive relapsed CTCL, including MF. ADCETRIS is not approved for the treatment of CTCL.

This orphan drug designation is a part of our ADCETRIS regulatory strategy, designed to complement the Special Protocol Assessment for the ongoing ALCANZA study, said Clay B. Siegall, President and Chief Executive Officer of Seattle Genetics. The encouraging data from investigator-sponsored trials of ADCETRIS in CTCL, which will be presented at ASH, provide further support for our activities in this patient population.

FDA orphan drug designation is intended to encourage companies to develop therapies for the treatment of diseases that affect fewer than 200,000 individuals in the United States. This designation provides Seattle Genetics with the opportunity for seven years of marketing exclusivity, grant funding to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential waiver of the FDA's application user fee.

The ALCANZA trial is a randomized phase III clinical trial of ADCETRIS for relapsed CD30-positive CTCL patients. The trial is assessing ADCETRIS versus investigators choice of methotrexate or bexarotene in patients with CD30-positive CTCL, including those with primary cutaneous anaplastic large cell lymphoma (pcALCL) or MF. The primary endpoint of the study is overall response rate lasting at least 4 months. Approximately 124 patients will be enrolled in the pivotal trial. The ALCANZA trial is being conducted under a Special Protocol Assessment agreement from the FDA. The study also received European Medicines Agency scientific advice. For more information about the ALCANZA trial, visit http://www.clinicaltrials.gov.

At the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA, data from two investigator-sponsored trials of ADCETRIS in CTCL will be reported:

Brentuximab vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable CD30 expression (Abstract #797)

Results of a phase II trial of brentuximab vedotin (SGN-35) for CD30-positive cutaneous T-cell lymphomas and lymphoproliferative disorders (Abstract #3688)

About ADCETRIS

ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

Continued here:
Seattle Genetics Receives FDA Orphan Drug Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides

Myriad Genetics' Prolaris Test Predicts Biochemical Recurrence in Prostate Cancer Patients Following Radiation Therapy

SALT LAKE CITY, Nov. 28, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) announced today that a presentation entitled "CCP Score Significantly Predicts PSA Failure After EBRT," was presented on Wednesday, November 28th, 2012 at the Annual Meeting of the Society of Urological Oncology in Bethesda, Maryland. The study demonstrates that the Prolaris(R) test, which measures cell cycle progression (CCP) genes, significantly predicts PSA biochemical recurrence in patients after treatment with external beam radiation therapy (EBRT).

Researchers at Durham VA Medical Center, Duke University School of Medicine, and Myriad Genetics analyzed biopsy specimens from 152 patients with prostate cancer. In this prospectively collected cohort, the Prolaris test was a significant predictor of biochemical recurrence in patients that had undergone radiation treatment (p=0.0017). After adjustment for Gleason score, PSA percent positive cores, and concurrent anti-hormone therapy, the Prolaris test accurately predicted those patients who would benefit from radiation therapy (p=0.034).

"Current approaches to the management of patients with prostate cancer lead to significant under and overtreatment of patients," said Dr. Stephen Freedland, Durham VA Medical Center and Duke University School of Medicine. "Measurement of the CCP score identifies prostate cancer patients at high risk of progression despite conventional radiation therapy who might be considered for more aggressive treatment regimens."

Approximately 25% of men who undergo primary radiation therapy will suffer potentially life threatening disease recurrence and progression. The Prolaris test could be used to identify these at-risk patients prior to their initial treatment. These patients may be appropriate candidates for more aggressive combination therapies such as radiation with anti-androgen therapy or chemotherapy.

The clinically important information that Prolaris provides cannot be obtained from currently available clinical parameters. In addition, this is the first Prolaris study that contained a significant number of African American men, a population known to be at especially high risk for aggressive prostate cancer.

About Prolaris

Prolaris is a genomic risk stratification test developed to aid physicians in predicting prostate cancer aggressiveness in conjunction with clinical parameters such as Gleason score and PSA. Prolaris is a direct molecular measure of prostate cancer tumor biology. By measuring the expression levels of genes involved with cancer replication, Prolaris is able to more accurately predict disease progression and enable physicians to better define a treatment/monitoring strategy for their patients. Prolaris is significantly more prognostic than currently used clinicopathologic variables and provides unique additional information that can be combined with other clinical factors to make the most accurate prediction of a patient's cancer aggressiveness and therefore disease progression.

Prolaris has been proven to predict clinical progression in 4 different clinical cohorts, in both pre and post-treatment scenarios.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

The rest is here:
Myriad Genetics' Prolaris Test Predicts Biochemical Recurrence in Prostate Cancer Patients Following Radiation Therapy

Gene Therapy against – Video


Gene Therapy against
From:HDTalkHealthDebateViews:0 0ratingsTime:05:23More inScience Technology

Continued here:
Gene Therapy against - Video

SCMOM 2012_Sistemic – Video


SCMOM 2012_Sistemic
Sistemic #39;s world leading expertise is on applying microRNA profiling in context with the biology, to areas where there is currently an unmet need for sophisticated tools delivering instructive and robust knowledge of the cell system. From their SistemQC trade; platform they have derived an extensive suite of tools for the cell therapy, gene therapy and bioprocessing community. SistemQC trade;, molecularly characterises cells including stem cells as well as aids in the optimization and monitoring (QC) of the manufacture process. More specifically the initial focus of SistemQC trade; by clients has been on generation of microRNA based ID markers, purity potency assessment and manufacture monitoring optimization. http://www.sistemic.co.uk Presenter: Jim Reid, Chairman and CEO, SistemicFrom:AllianceRegenMedViews:3 1ratingsTime:11:56More inScience Technology

Original post:
SCMOM 2012_Sistemic - Video

Episode 1. Uncovering Genetic Code – Video


Episode 1. Uncovering Genetic Code
#12298;Unveiling the Secrets of Biotechnology #65306;Volume #8741; #12299; Part 1 #65306;Secrets Left by Our Ancestors Part 2 #65306;The Antidote to Rare Diseases -- Gene Therapy Part 3 #65306;Opening DNA #39;s Pandora #39;s BoxFrom:ccleestagViews:0 0ratingsTime:23:34More inScience Technology

Read more:
Episode 1. Uncovering Genetic Code - Video

Gene Therapy – Wiki Article – Video


Gene Therapy - Wiki Article
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual #39;s cells as a therap... Gene Therapy - Wiki Article - wikiplays.org Original @ http All Information Derived from Wikipedia using Creative Commons License: en.wikipedia.org Author: Unknown Image URL: en.wikipedia.org ( This work is in the Public Domain. )From:WikiPlaysViews:0 0ratingsTime:33:40More inEducation

See original here:
Gene Therapy - Wiki Article - Video

NeoStem (NYSE MKT: NBS): RedChip Money Report (Air Date Nov. 17, 2012) – Video


NeoStem (NYSE MKT: NBS): RedChip Money Report (Air Date Nov. 17, 2012)
NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.From:RedChip Money Report GentryViews:12 0ratingsTime:04:19More inScience Technology

Read this article:
NeoStem (NYSE MKT: NBS): RedChip Money Report (Air Date Nov. 17, 2012) - Video

1 SCOM 2012 GEKarolinskaPartnership Final PGM – Video


1 SCOM 2012 GEKarolinskaPartnership Final PGM
Firman Ghouze, Ph.D., Director, Cell Therapy, GE Healthcare Rolf Hultcrantz, MD, Professor, Gastroenterology and Hepatology, Karolinska Institutet, Karolinska University Hospital Johan Permert, MD, Professor, Chairman, Development and Innovation, Karolinska University HospitalFrom:AllianceRegenMedViews:0 0ratingsTime:28:54More inScience Technology

See the rest here:
1 SCOM 2012 GEKarolinskaPartnership Final PGM - Video

Archives